 |
|
|
Megestrol
|
|
| Systematic (IUPAC) name | |
| 17-acetyl-17-hydroxy-6,10, 13-trimethyl-2,8,9,11,12,14,15,16- octahydro-1H-cyclopenta[ a] phenanthren-3-one | |
| Identifiers | |
| CAS number | 3562-63-8 |
| ATC code | G03AC05 G03, L02 |
| PubChem | 19090 |
| DrugBank | APRD01092 |
| Chemical data | |
| Formula | C22H30O3 |
| Mol. mass | 342.472 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | 34 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
contraindicated |
| Legal status | |
| Routes | ? |
 (what is this?) (verify) |
|
Megestrol is a progesterone derivative with antineoplastic properties used in the treatment of advanced carcinoma of the breast and endometrium. When given in relatively high doses, Megestrol can substantially increase appetite in most individuals, even those with advanced cancer.
Megestrol Acetate Oral Suspension (a form of Megestrol) is used primarily as an appetite enhancer. The method of appetite enhancement is not known, but it can cause high blood sugar.[1]
Currently, it is manufactured under the trade name Megace.[2]
It may cause adrenal insufficiency.[3]
References
- ^ "Megace ES Side Effects | Megace ES (megestrol acetate)". http://www.megacees.com/megacees-side-effects.html. Retrieved 2009-05-17.
- ^ "Malnutrition and Cachexia Treatment | Megace ES (megestrol acetate)". http://www.megacees.com/. Retrieved 2009-05-17.
- ^ Bulchandani D, Nachnani J, Amin A, May J (August 2008). "Megestrol acetate-associated adrenal insufficiency". Am J Geriatr Pharmacother 6 (3): 167–72. doi:. PMID 18775392. http://linkinghub.elsevier.com/retrieve/pii/S1543-5946(08)00043-3.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
This medical treatment article is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)
